Comparative Pharmacology
Head-to-head clinical analysis: BARHEMSYS versus EMRELIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BARHEMSYS versus EMRELIS.
BARHEMSYS vs EMRELIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BARHEMSYS (amisulpride) is a selective dopamine D2/D3 receptor antagonist. It also has weak affinity for serotonin 5-HT2A and 5-HT2B receptors, with no significant activity at other dopamine or serotonin receptor subtypes. Its antiemetic effect is primarily mediated through blockade of D2 receptors in the chemoreceptor trigger zone (CTZ).
Emrelis is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2, thereby activating T-cell-mediated antitumor immune response.
BARHEMSYS (amisulpride) 10 mg intravenously over 2 minutes, once daily for prevention of postoperative nausea and vomiting.
100 mg subcutaneously once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily dosing in most patients.
12 hours (terminal); dosing interval adjusted in renal impairment (CrCl <30 mL/min)
Renal excretion accounts for approximately 50% of the dose as unchanged drug; fecal elimination (including biliary) accounts for approximately 30-40%.
Renal: 70% unchanged; fecal: 15%; biliary: 10%
Category C
Category C
Antiemetic
Antiemetic